




Recovering Hearts. Saving Lives.™

Q4 FY 2018 Earnings Call

Financial Results & Operational Highlights

FINANCIAL RESULTS, Q4 FY 2018


Revenue (\$M) & Growth Rate




Cash (\$M)



Gross Margin %




Operating Margin %




FINANCIAL RESULTS, ANNUALLY


Revenue (\$M) & Growth Rate




Cash (\$M)



Gross Margin %




Operating Margin %




U.S. UTILIZATION MIX, Q4 FY 2018

Revenue by Impella Device




Utilization by Indication*



Abiomed Revenue Growth:
40%

U.S. Patient Growth:
35%

U.S. Hospital Site Penetration



* Protected PCI patients are elective and urgent PCI patients. Emergent includes AMI cardiogenic shock, post-surgery shock and other shock.

ABIOMED FY 2019 GUIDANCE, AS OF MAY 3, 2018

Abiomed FY'19
Guidance

Revenue

\$740 - \$770M ; +25 - 30% YOY

Operating Margin %

28 - 30%